Aptamer Sciences Inc.
Financials
Valuation Metrics
Aptamer Sciences Inc.'s Market Cap is ₩474B. At end of 2025 it was ₩463B. Ranked #1800 of 2,421 in KR market (top 74%), #1100 of 1,640 on KOSDAQ (top 67%), #191 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 83%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 47.40B KRW | KR#1,800/2,421 Sec#191/231 |
| Revenue | 5.40B KRW | KR#2,336/2,421 Sec#193/231 |
| Net Income | -11.65B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 68.55B KRW | KR#2,023/2,421 Sec#166/231 |
| Net Assets | 42.25B KRW | KR#2,015/2,421 Sec#174/231 |
| Employees | 55 | KR#2,014/2,421 Sec#184/231 |
| Value | ||
| P/B | 1.12x | KR#1,563/2,421 Sec#104/231 |
| P/S | 8.78x | KR#2,257/2,421 Sec#161/231 |
| FCF Yield | -20.45% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -27.57% | KR#2,160/2,421 Sec#171/231 |
| ROA | -17.00% | KR#2,215/2,421 Sec#172/231 |
| Op. Margin | -159.14% | KR#2,327/2,421 Sec#183/231 |
| Revenue Growth | 143.57% | KR#57/2,421 Sec#12/231 |
| Financial Health | ||
| Debt Ratio | 62.23% | KR#1,121/2,421 Sec#132/231 |
| Total Debt | 13.90B KRW | KR#1,518/2,421 Sec#131/231 |
| FCF | -9.69B KRW | KR#1,699/2,421 Sec#146/231 |
| Cash | 17.89B KRW | KR#1,310/2,421 Sec#101/231 |
| Current Ratio | 1.27x | KR#1,429/2,421 Sec#151/231 |
| Performance | ||
| 1Y Return | -28.04% | KR#1,501/2,421 Sec#115/231 |
| 1M Return | -15.51% | KR#2,248/2,421 Sec#191/231 |
| From 52W High | -61.14% | KR#1,898/2,421 Sec#150/231 |
| 1Y MDD | -64.45% | KR#1,720/2,421 Sec#145/231 |
| Trading | ||
| Volume | 5,487 shares | KR#2,104/2,421 Sec#202/231 |
| Trading Value | 8.5M KRW | KR#2,294/2,421 Sec#218/231 |
| Foreign Own. | 20.07% | KR#227/2,421 Sec#11/231 |
| Per Share | ||
| EPS | -382 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,384 KRW | KR#2,220/2,421 Sec#194/231 |
Company Info
Aptamer Sciences, established in 2011 as a POSTECH spin-off, listed on KOSDAQ in 2020 and expanded into the Contract Research Organization (CRO) business by acquiring ISS in 2024. The company is developing solid and blood cancer therapeutics leveraging its aptamer technology platform, with its flagship product, Aptodetect Lung, being an excellent in-vitro diagnostic kit. Aptamer Sciences is further building expertise in biopharmaceutical analysis and establishing a comprehensive new drug development system to advance next-generation anticancer drug development.